Pharmafile Logo
Pharmafocus logo
Advanced Search

BMS

Showing 15 posts of 286 posts found.

Bristol-Myers Squibb makes three senior management changes

October 24, 2011
Medical Communications, Research and Development, Sales and Marketing BMS

BMS has made three changes to its senior management with Giovanni Caforio promoted to president of US pharmaceuticals and Charles …

Appointment

Amgen poaches Tony Hooper from Bristol-Myers Squibb

October 21, 2011
Medical Communications Amgen, BMS

Amgen has appointed Tony Hooper as the new executive vice president of global commercial operations. Hooper, 56, joins Amgen after …

Appointment

NICE says no to BMS for second-line Orencia

August 25, 2011
Sales and Marketing BMS, NICE, Orencia, rheumatoid arthritis

In final draft guidance NICE has not recommended the use of Bristol-Myers Squibb’s arthritis drug Orencia after other drugs have …

News

BMS makes $325m biotech acquisition

July 25, 2011
Research and Development, Sales and Marketing BMS, biotech, research and development news

Bristol-Myers Squibb is to plug gaps in its pipeline by buying private biotech company Amira Pharmaceuticals for $325 million in …

News

Future of AZ-BMS diabetes drug in doubt

July 20, 2011
Research and Development, Sales and Marketing AstraZeneca, BMS, dapagliflozin, diabetes, research and development news

A US advisory committee has rejected an investigational compound for type II diabetes sufferers, throwing its future into doubt. Dapagliflozin, …

News

European approval for BMS skin cancer vaccine

July 14, 2011
Sales and Marketing BMS, Yervoy, ipilimumab

Bristol-Myers Squibb’s skin cancer vaccine Yervoy has been approved in Europe after showing survival benefits in one of the most …

News

BMS licences potential first-in-class cancer biologic

July 7, 2011
Research and Development BMS, Cancer, biologics

Bristol-Myers Squibb has signed a $465 million deal for the rights to a potential first-in-class treatment for cancer. IPH2102 is …

News

European approval for BMS kidney transplant drug Nulojix

June 22, 2011
Sales and Marketing BMS, EMA, Nulojix, transplant

European regulators have followed their US counterparts in granting marketing authorisation for a drug which aims to prevent kidney transplant …

News

BMS and Roche to team up in melanoma

June 3, 2011
Sales and Marketing BMS, Roche, melanoma, oncology

Bristol-Myers Squibb and Roche are to use two of their drugs in an exploratory phase I/II study a bid to …

News

Pfizer and BMS’ blood thinner Eliquis approved in Europe

May 23, 2011
Sales and Marketing BMS, Eliquis, Pfizer, apixaban

Pfizer and Bristol-Myers Squibb’s eagerly anticipated blood thinner Eliquis has gained European approval. A twice-daily oral Factor Xa inhibitor, Eliquis …

News
Sanofi-Aventis' Plavix (clopidogrel)

Plavix sales plummet in England

May 5, 2011
Sales and Marketing BMS, Plavix, Sanofi-Aventis, clopidogrel

GP prescriptions for Plavix saw a significant drop in England last year as doctors opted for cheaper generic forms of …

News

New BMS drug trumps peg-interferon alpha

April 4, 2011
Research and Development, Sales and Marketing BMS, EASL, hepatitis C, pegintron alfa

Bristol-Myers Squibb has been given a boost by trial results which suggest its compound for hepatitis C, PEG-Interferon lambda, is …

News

New melanoma drug approved by FDA

March 28, 2011
Sales and Marketing BMS, melanoma

Yervoy, Bristol Myers Squibb’s new treatment for advanced skin cancer has gained approval in the US. The drug is the …

News

BMS skin cancer vaccine hits phase III target

March 23, 2011
Research and Development BMS, Bristol-Myers Squibb, advanced inoperable skin cancer, advanced melanoma, cancer drugs, cancer vaccine, ipilimumab

Bristol Myers Squibb’s cancer vaccine ipilimumab has increased overall survival in advanced melanoma patients. The therapy was being tested as …

News

Onglyza expands European licence

March 4, 2011
Sales and Marketing AZ, AstraZeneca, BMS, Bristol-Myers Squibb, Onglyza, diabetes, renal impairment, saxagliptin, type II diabetes

European regulators have approved a licence extension for diabetes treatment Onglyza, making it the first drug in its class that …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025